Literature DB >> 21438001

Fetal RHD genotyping by analysis of maternal plasma in a mixed population.

Daphne R T Amaral1, Débora C Credidio, Jordão Pellegrino, Lilian Castilho.   

Abstract

BACKGROUND: Maternal plasma analysis for the determination of the fetal RHD status is an exciting tool for the management of RhD-negative pregnant women, specially sensitized women. We assessed the accuracy of fetal RHD genotyping by analysis of maternal plasma in a multi-ethnic population.
METHODS: We analyzed plasma samples from 88 RhD-negative pregnant women between 11 and 39 weeks of gestation, median age of 28 years old to determine the fetal RHD genotype. This population was from Southeastern Brazil with high mixed ethnic background. Fourteen patients (16%) had anti-D alloantibody. We used Taqman primers and probes to detect by real-time PCR, exons 4, 5, and 10 of RHD. As internal controls we used primers/probes sets to SRY and CCR5. Peripheral or umbilical cord bloods from respective neonates were collected during delivery and hemagglutination was performed.
RESULTS: Fifty-eight samples (66%) were genotyped as RHD+, 27 samples (31%) showed complete absence of RHD and 3 samples (3 %) presented a D variant (RHDψ). All the results agreed with the neonatal typing, including the three fetuses with the RHDψ, phenotyped as RhD-negative. Thus, the accuracy of the fetal RHD genotyping in this mixed population was 100%. The earliest pregnancy in which fetal RHD was detected was 11 weeks.
CONCLUSION: Our findings indicate that the accuracy of RHD gene using three regions (exons 4, 5, and 10) can be sufficient for clinical application in a multi-ethnic population. This knowledge helped us on the development of a feasible protocol for fetal RHD genotyping on DNA from maternal plasma for our population.
© 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21438001      PMCID: PMC6647733          DOI: 10.1002/jcla.20440

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  27 in total

1.  Determination of fetal RhD status by maternal plasma DNA analysis.

Authors:  J Zhang; C Fidler; M F Murphy; P F Chamberlain; I L Sargent; C W Redman; N M Hjelm; J S Wainscoat; Y M Lo
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

2.  Risk free simultaneous prenatal identification of fetal Rhesus D status and sex by multiplex real-time PCR using cell free fetal DNA in maternal plasma.

Authors:  X Y Zhong; W Holzgreve; S Hahn
Journal:  Swiss Med Wkly       Date:  2001-02-10       Impact factor: 2.193

3.  Variation in the reliability of RHD antenatal genotyping using the polymerase chain reaction and targeting multiple exons of the RHD gene.

Authors:  L Johnson; S A McCracken; J M Morris; N B Woodland; R L Flower
Journal:  Vox Sang       Date:  2003-10       Impact factor: 2.144

4.  Detection of fetal Rhesus D gene in whole blood of women booking for routine antenatal care.

Authors:  Michael J Turner; Cara M Martin; John J O'Leary
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2003-05-01       Impact factor: 2.435

Review 5.  Haemolytic disease of the newborn.

Authors:  Neil A Murray; Irene A G Roberts
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-03       Impact factor: 5.747

Review 6.  Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects.

Authors:  Geoff Daniels; Kirstin Finning; Pete Martin; Edwin Massey
Journal:  Prenat Diagn       Date:  2009-02       Impact factor: 3.050

7.  The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible.

Authors:  Sina P Müller; Iris Bartels; Werner Stein; Günther Emons; Kai Gutensohn; Michael Köhler; Tobias J Legler
Journal:  Transfusion       Date:  2008-08-07       Impact factor: 3.157

8.  Detection of fetal RHD-specific sequences in maternal plasma.

Authors:  B H Faas; E A Beuling; G C Christiaens; A E von dem Borne; C E van der Schoot
Journal:  Lancet       Date:  1998-10-10       Impact factor: 79.321

9.  Blood group genotyping in a population of highly diverse ancestry.

Authors:  J Pellegrino; L Castilho; M Rios; C A De Souza
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

10.  Evaluation of the clinical usefulness of isolation of fetal DNA from the maternal circulation.

Authors:  Sashi C Siva; Sylvia I Johnson; Sharon A McCracken; Jonathan M Morris
Journal:  Aust N Z J Obstet Gynaecol       Date:  2003-02       Impact factor: 2.100

View more
  4 in total

1.  Determination of Fetal RHD Genotype Including the RHD Pseudogene in Maternal Plasma.

Authors:  Karen Chinoca Ziza; Adolfo Wenjaw Liao; Marcia Dezan; Carla Luana Dinardo; Eduardo Jens; Rossana Pulcineli Vieira Francisco; Alfredo Mendrone Junior; Marcelo Zugaib; José Eduardo Levi
Journal:  J Clin Lab Anal       Date:  2016-09-06       Impact factor: 2.352

2.  Fetal RHD Genotyping from Circulating Cell-Free Fetal DNA in Plasma of Rh Negative Pregnant Women in Iran.

Authors:  Mohammad Hossein Ahmadi; Sedigheh Hantuoshzadeh; Mohammad Ali Okhovat; Nahid Nasiri; Azita Azarkeivan; Naser Amirizadeh
Journal:  Indian J Hematol Blood Transfus       Date:  2015-11-06       Impact factor: 0.900

3.  Fetal Rhesus D Genotyping and Sex Determination from Maternal Plasma of Rhesus D-Negative Antenatal Population: The Usefulness of Conventional Polymerase Chain Reaction in Resource-limited Settings.

Authors:  Otchere Addai-Mensah; Edward Y Afriyie; Samuel Asamoah Sakyi; Christian Obirikorang; Max Efui Annani-Akollor; Eddie-Williams Owiredu; Francis A Amponsah; Richard Vikpebah Duneeh; Evans Asamoah Adu
Journal:  Obstet Gynecol Int       Date:  2020-10-16

4.  Genotyping approach for non-invasive foetal RHD detection in an admixed population.

Authors:  Carolina Trucco Boggione; Melina E Luján Brajovich; Stella M Mattaloni; René A Di Mónaco; Silvia E García Borrás; Claudia S Biondi; Carlos M Cotorruelo
Journal:  Blood Transfus       Date:  2016-03-21       Impact factor: 3.443

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.